دورية أكاديمية
أعرض في EDS

Management of dyslipidaemia in individuals with severe mental illness: a population-based study in the Greater Copenhagen Area.

التفاصيل البيبلوغرافية
العنوان: Management of dyslipidaemia in individuals with severe mental illness: a population-based study in the Greater Copenhagen Area.
المؤلفون: Høgnason Mohr G; Center for Neuropsychiatric Schizophrenia Research, Mental Health Centre Glostrup, University of Copenhagen, Nordstjernevej 41, 2600 Glostrup, Denmark., Barcella CA; Department of Cardiology, Copenhagen University Hospital Herlev and Gentofte, University of Copenhagen, Hellerup, Denmark.; Department of Internal Medicine, Nykøbing Falster Hospital, Nykøbing Falster, Denmark., Grand MK; Research Unit for General Practice and Section of General Practice, Department of Public Health, University of Copenhagen, Copenhagen, Denmark.; Section of Biostatistics, Department of Public Health, University of Copenhagen, Copenhagen, Denmark., Kriegbaum M; Research Unit for General Practice and Section of General Practice, Department of Public Health, University of Copenhagen, Copenhagen, Denmark., Siersma V; Research Unit for General Practice and Section of General Practice, Department of Public Health, University of Copenhagen, Copenhagen, Denmark., Hahn MK; Center for Neuropsychiatric Schizophrenia Research, Mental Health Centre Glostrup, University of Copenhagen, Glostrup, Denmark.; Centre for Addiction and Mental Health, Department of Psychiatry, University of Toronto, Toronto, ON, Canada., Agarwal SM; Centre for Addiction and Mental Health, Department of Psychiatry, University of Toronto, Toronto, ON, Canada., Bakkedal C; Research Unit for General Practice and Section of General Practice, Department of Public Health, University of Copenhagen, Copenhagen, Denmark., Baandrup L; Center for Neuropsychiatric Schizophrenia Research, Mental Health Centre Glostrup, University of Copenhagen, Glostrup, Denmark.; Mental Health Centre Copenhagen, Bispebjerg-Gentofte, Copenhagen NV, Denmark.; Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark., Knop FK; Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.; Center for Clinical Metabolic Research, Gentofte Hospital, University of Copenhagen, Hellerup, Denmark.; Steno Diabetes Center Copenhagen, Gentofte, Denmark., Andersen CL; Research Unit for General Practice and Section of General Practice, Department of Public Health, University of Copenhagen, Copenhagen, Denmark.; Department of Hematology, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark., Ebdrup BH; Center for Neuropsychiatric Schizophrenia Research, Mental Health Centre Glostrup, University of Copenhagen, Glostrup, Denmark.; Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
المصدر: Therapeutic advances in psychopharmacology [Ther Adv Psychopharmacol] 2023 Nov 17; Vol. 13, pp. 20451253231211574. Date of Electronic Publication: 2023 Nov 17 (Print Publication: 2023).
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Sage Country of Publication: England NLM ID: 101555693 Publication Model: eCollection Cited Medium: Print ISSN: 2045-1253 (Print) Linking ISSN: 20451253 NLM ISO Abbreviation: Ther Adv Psychopharmacol Subsets: PubMed not MEDLINE
أسماء مطبوعة: Original Publication: London : Sage
مستخلص: Background: Severe mental illness (SMI) is associated with increased cardiovascular risk. Dyslipidaemia is a potentially modifiable risk factor, which may be inadequately managed in patients with SMI.
Objectives: To assess management of dyslipidaemia in patients with SMI versus healthy controls (HCs) in 2005 and 2015.
Design and Methods: Using Danish registers, we identified adult patients with SMI in the Greater Copenhagen Area (schizophrenia spectrum disorders or bipolar disorder) with ⩾1 general practitioner contact in the year before 2005 and 2015, respectively, and HCs without SMI matched on age and gender (1:5). Outcomes were lipid-profile measurements, presence of dyslipidaemia and redemption of lipid-lowering pharmacotherapy. Differences in outcomes between patients with SMI and controls were measured with multivariable logistic regression.
Results: We identified 7217 patients with SMI in 2005 and 9939 in 2015. After 10 years, patients went from having lower odds of lipid measurements to having higher odds of lipid measurements compared with HCs [odds ratio (OR) 2005 0.70 (99% confidence interval (CI) 0.63-0.78) versus OR 2015 1.34 (99% CI 1.24-1.44); p 2005 versus 2015  < 0.01]. Patients had higher odds of dyslipidaemia during both years [OR 2005 1.43 (99% CI 1.10-1.85) and OR 2015 1.23 (99% CI 1.08-1.41)]. Patients went from having lower odds of receiving lipid-lowering pharmacotherapy to having higher odds of receiving lipid-lowering pharmacotherapy [OR 2005 0.77 (99% CI 0.66-0.89) versus OR 2015 1.37 (99% CI 1.24-1.51); p 2005 versus 2015  < 0.01]. However, among persons at high cardiovascular risk, patients had lower odds of receiving lipid-lowering pharmacotherapy during both years, including subsets with previous acute coronary syndrome [OR 2005 0.30 (99% CI 0.15-0.59) and OR 2015 0.44 (99% CI 0.24-0.83)] and ischaemic stroke or transient ischaemic attack (TIA) [OR 2005 0.43 (99% CI 0.26-0.69) and OR 2015 0.61 (99% CI 0.41-0.89)].
Conclusion: These results imply an increased general awareness of managing dyslipidaemia among patients with SMI in the primary prophylaxis of cardiovascular disease. However, secondary prevention with lipid-lowering drugs in patients with SMI at high cardiovascular risk may be lacking.
Competing Interests: BE is part of the Advisory Board of Eli Lilly Denmark A/S, Janssen-Cilag, Lundbeck Pharma A/S, and Takeda Pharmaceutical Company Ltd, and has received lecture fees from Bristol-Myers Squibb, Boehringer Ingelheim, Otsuka Pharma Scandinavia AB, Eli Lilly Company and Lundbeck Pharma A/S. FKK has served on scientific advisory panels and/or been part of speaker’s bureaus for, served as a consultant to and/or received research support from Amgen, AstraZeneca, Boehringer Ingelheim, Carmot Therapeutics, Eli Lilly, Gubra, MedImmune, MSD/Merck, Mundipharma, Norgine, Novo Nordisk, Sanofi, ShouTi, Zealand Pharma and Zucara. The other authors declare no conflict of interests.
(© The Author(s), 2023.)
References: World Psychiatry. 2017 Jun;16(2):163-180. (PMID: 28498599)
BMJ Open. 2020 May 24;10(5):e034318. (PMID: 32448791)
Diabetes Care. 2004 Feb;27(2):596-601. (PMID: 14747245)
Circulation. 2015 Sep 8;132(10):965-86. (PMID: 26260736)
Front Psychiatry. 2021 Mar 17;12:642403. (PMID: 33815174)
Scand J Public Health. 2011 Jul;39(7 Suppl):91-4. (PMID: 21775362)
Scand J Public Health. 2011 Jul;39(7 Suppl):54-7. (PMID: 21775352)
Scand J Public Health. 2011 Jul;39(7 Suppl):30-3. (PMID: 21775347)
Scand J Public Health. 2011 Jul;39(7 Suppl):38-41. (PMID: 21775349)
Eur Heart J. 2020 Jan 1;41(1):111-188. (PMID: 31504418)
Nord J Psychiatry. 2022 Nov;76(8):602-609. (PMID: 35200088)
Alcohol Alcohol. 2020 Aug 14;55(5):531-539. (PMID: 32588881)
Lancet Psychiatry. 2017 Dec;4(12):937-945. (PMID: 29122573)
BMC Psychiatry. 2015 Mar 21;15:55. (PMID: 25885367)
Lancet. 2019 Nov 16;394(10211):1827-1835. (PMID: 31668728)
J Am Heart Assoc. 2019 Aug 20;8(16):e012708. (PMID: 31423870)
Asian J Psychiatr. 2021 Mar;57:102583. (PMID: 33581368)
Resuscitation. 2019 Oct;143:180-188. (PMID: 31325557)
Neuropsychiatr Dis Treat. 2017 Feb 28;13:621-630. (PMID: 28280344)
Heart. 2007 Oct;93(10):1256-62. (PMID: 17344333)
World Psychiatry. 2011 Feb;10(1):52-77. (PMID: 21379357)
PLoS One. 2016 Nov 17;11(11):e0166429. (PMID: 27855222)
Acta Psychiatr Scand. 2009 Oct;120(4):274-80. (PMID: 19426161)
Eur Psychiatry. 2021 Jan 08;64(1):e7. (PMID: 33413701)
Eur Psychiatry. 2016 May;35:8-15. (PMID: 27061372)
Psychiatr Serv. 2012 Jul;63(7):693-701. (PMID: 22588231)
Diabetes Metab Syndr. 2015 Jul-Sep;9(3):168-76. (PMID: 25943411)
Scand J Public Health. 2011 Jul;39(7 Suppl):34-7. (PMID: 21775348)
Arch Gen Psychiatry. 2010 Jan;67(1):17-24. (PMID: 20048219)
Heart. 2021 Oct;107(19):1544-1551. (PMID: 33452118)
BMC Psychiatry. 2016 May 12;16:141. (PMID: 27176477)
Lancet Public Health. 2019 Feb;4(2):e89-e96. (PMID: 30446416)
Schizophr Res. 2019 Apr;206:284-290. (PMID: 30446270)
JAMA Psychiatry. 2018 Dec 1;75(12):1234-1240. (PMID: 30422158)
Acta Psychiatr Scand. 2019 Apr;139(4):348-360. (PMID: 30697685)
World J Diabetes. 2017 Aug 15;8(8):390-396. (PMID: 28861176)
PLoS One. 2020 Mar 27;15(3):e0230674. (PMID: 32218598)
World Psychiatry. 2015 Jun;14(2):119-36. (PMID: 26043321)
Scand J Public Health. 2011 Jul;39(7 Suppl):22-5. (PMID: 21775345)
Am J Psychiatry. 2009 Mar;166(3):345-53. (PMID: 19147694)
J Am Heart Assoc. 2022 Mar 15;11(6):e021444. (PMID: 35261265)
فهرسة مساهمة: Keywords: bipolar disorder; dyslipidaemia; lipid-lowering pharmacotherapy; schizophrenia; severe mental illness
تواريخ الأحداث: Date Created: 20231129 Latest Revision: 20231201
رمز التحديث: 20231201
مُعرف محوري في PubMed: PMC10656803
DOI: 10.1177/20451253231211574
PMID: 38022836
قاعدة البيانات: MEDLINE
الوصف
تدمد:2045-1253
DOI:10.1177/20451253231211574